Compare MED & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MED | ACOG |
|---|---|---|
| Founded | 1980 | 2000 |
| Country | United States | Canada |
| Employees | N/A | 57 |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.6M | 110.4M |
| IPO Year | 1996 | N/A |
| Metric | MED | ACOG |
|---|---|---|
| Price | $10.90 | $5.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $12.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 183.5K | 72.4K |
| Earning Date | 05-04-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $934,842,000.00 | N/A |
| Revenue This Year | N/A | $139.22 |
| Revenue Next Year | N/A | $134.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.22 | $4.50 |
| 52 Week High | $15.37 | $10.88 |
| Indicator | MED | ACOG |
|---|---|---|
| Relative Strength Index (RSI) | 55.43 | 41.16 |
| Support Level | $10.14 | $5.74 |
| Resistance Level | $10.87 | $6.59 |
| Average True Range (ATR) | 0.29 | 0.47 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 73.11 | 7.00 |
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.